HOME >> BIOLOGY >> NEWS
Therapeutic cloning may be permitted at Newcastle University

A special licensing committee of the UK Human Fertilization & Embryology Authority (HFEA) met on June 16 in London to decide whether to grant a license to scientists at The Center for Life at Newcastle University. If approved, this will be the first license to begin research involving cell nuclear replacement (therapeutic cloning), focusing on the treatment of diabetes in the UK and will be a first in Europe.

Therapeutic cloning, for the derivation of embryonic stem cells, has the potential to lead to cures for serious diseases such as Alheizmer's, Parkinson's, heart failure and cancer. The UK has a strict regulatory system for human embryonic stem cell research. If the license is approved, it will allow this important work to begin. The UK was one of the first countries in the world to pass legislation to explicitly ban reproductive cloning.

Dr. Miodrag Stojkovic of Newcastle University who leads the research team said that he was very happy that the law in the UK allows scientists to work in this very promising field and use their knowledge in stem cell biology and nuclear transfer technique to bring faster and more efficient stem cells from the bench to the patient's bed.

Newcastle University's Institute of Human Genetics and the Life Fertility Center is one of only two groups in the UK to derive human ES (embryonic stem cells) from spare IVF embryos.

ES cells can be used to make any cell type in the body and replace cells that have been lost as a result of disease or injury. Cells derived from ES cells may often be genetically different from the patient, and transplanted cells could be rejected by the patient's immune system.

The Newcastle stem cell group will use nuclear transfer to derive stem cells that are genetically identical to those of a patient. In this case the stem cells and cells derived from them would not be rejected after being transplanted into a p
'"/>

Contact: Chris Pook
Chris.Pook@fco.gov.uk
202-588-6674
British Information Services
17-Jun-2004


Page: 1 2

Related biology news :

1. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
2. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. Therapeutic cloning no longer a dream, says scientist who produced first cloned embryonic stem cell
4. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
5. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
6. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
7. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
8. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
9. Immerge BioTherapeutics announces identification of PERV receptor
10. Hemocellular Therapeutics establishes licensing agreement with UNC, ECU
11. Dana-Farber launches NFCR Center for Therapeutic Antibody Research and Engineering

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Therapeutic cloning may permitted Newcastle University

(Date:6/18/2013)... and 10% of breast and ovarian cancers are familial ... are attributable to inherited mutations from the parents in ... these mutations, PARP inhibitors, which are currently in clinical ... new option for personalised cancer treatment, an alternative to ... fraction of these patients generate resistance to the drug ...
(Date:6/17/2013)... in the U.S. exposed to high levels of air pollution ... a child with autism as women who lived in areas ... School of Public Health (HSPH). It is the first large ... across the U.S. , "Our findings raise concerns since, depending ... our study lived in areas where risk of autism was ...
(Date:6/17/2013)... their food may turn out to be just as important ... of St. Michael,s Hospital. , The study, led by ... association between poor eating habits in kids ages three to ... cholesterol, putting them at risk for cardiovascular disease later in ... Medical Association Journal today. , "We know that ...
Breaking Biology News(10 mins):An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2Poor eating behaviors may put preschoolers at risk for later health problems 2
(Date:6/19/2013)... Indiana (PRWEB) June 19, 2013 ... joined the speaking faculty at 2013’s BioLogistics Summit ... The conference, coordinated by Cold Chain IQ and ... biologics. This “complexity” is, in part, attributed to ... , “Implicit within these trends is an ...
(Date:6/19/2013)... 2013 Adding to their already extensive ... with Simport’s Dropette® and Heathrow Scientific disposable plastic ... doing basic biology, chemistry and any type of liquid ... over 35 years, Simport has been supplying the science ... like the Simport Dropette®. Simport’s Dropette® is a one-piece ...
(Date:6/18/2013)... June 18, 2013 (PRWEB) June 18, 2013 ... and attendance system in North America, has introduced ... employee data and payroll records between ExakTime’s software ... automates ExakTime software setup and keeps employee ... employee data from a business’ current payroll software, ...
(Date:6/18/2013)... AZ (PRWEB) June 18, 2013 Nasseo, ... 2013 Innovation Challenge Winner out of hundreds of applicants ... its spring Arizona Innovation Challenge . The Arizona ... country for a technology commercialization challenge, granting a financial ... most promising technology ventures. Nasseo’s state of the art ...
Breaking Biology Technology:BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes 2ExakTime Introduces AccountLinx Plus 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2
Cached News: